Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a double-blind, placebo-controlled Phase II trial of 181 patients, significantly more MLN-02 patients met the primary endpoint of clinical remission
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury